Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 85,971 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Obesity
Interventions: Intervention Control, Counselling, Contrave, Contrave and Counseling; Behavioral · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Scottsbluff, Nebraska

Conditions: Renal Impairment, Healthy Volunteers
Interventions: rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Cerebral Vasospasm
Interventions: Nicardipine hydrochloride, Preservative-free normal saline; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Obesity
Interventions: group fitness + education, group fitness classes only; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Lymphoma
Interventions: PARASYM neuromodulation device; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Tulsa, Oklahoma

Conditions: Peripheral Arterial Disease
Interventions: Blood Flow Restriction Cuff System, Low-load Resistance Training, High-load Resistance Training; Behavioral
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Parkinson's Disease
Interventions: Nicotinamide Riboside (NR), Oral placebo capsules; Dietary Supplement
Lead sponsor: University of Oklahoma; Other
Eligibility: 55 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Glioblastoma Multiforme
Interventions: Avastin; Drug
Lead sponsor: Brain & Spine Surgeons of New York; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Hemophilia A
Interventions: FVIII products, Conventional FVIII replacement therapies; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Oral Lichen Planus
Interventions: Pimecrolimus 1% cream; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Aortic Stenosis
Interventions: Portable 1-lead electrocardiogram, Point-of-care ultrasound, AI-ECG risk algorithm, AI-POCUS; Diagnostic Test · Other
Lead sponsor: Yale University; Other
Eligibility: 70 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Houston, Texas

Conditions: Math Knowledge
Interventions: Heroes of Knowledge, Attention/Time Control Game; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 5 Years to 8 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml; Drug
Lead sponsor: Edda Spiekerkoetter; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Escondido, California • La Jolla, California • San Mateo, California + 16 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
Interventions: Berzosertib, Biopsy Specimen, Biospecimen Collection, Computed Tomography, Irinotecan Hydrochloride; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more

Conditions: Hepatocellular Carcinoma
Interventions: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Orange, California + 9 more

Conditions: Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Interventions: Somatostatin Analogue(s); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: San Francisco, California • St Louis, Missouri

Conditions: Influenza
Interventions: Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine; Biological
Lead sponsor: Colby Pharmaceutical Company; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Dexlansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: Healthy Volunteer
Interventions: Denosumab CP4, Denosumab CP2; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Conditions: Non Small-cell Lung Cancer
Interventions: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Pain, Chronic Pain Syndrome
Interventions: Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST), Mind Body Intervention 2; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Pain
Interventions: HTX-011, Luer Lock applicator, Vial access device, aprepitant; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

Safety Study of Nicardipine to Treat Cerebral Vasospasm

Randomized Controlled Trial Targeting Obesity-related Behaviors

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center

NAD Supplementation in Parkinson's Disease

Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

Pimecrolimus Cream for Oral Lichen Planus

Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study

Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

Liquid Biopsy for Early Non-small Lung Cancer Detection

Mind Body Therapy for the Treatment of Chronic Pain

Phase 2 Bunionectomy HTX-011 Administration Study